Instructions and Guidelines : Journal of Addiction Medicine

Journal Logo

​​​​​​​​

Instructions and Guidelines

 
JOURNAL SCOPE
ETHICAL/LEGAL CONSIDERATIONS
     
Patient anonymity and informed consent
     
Protection of Human Subjects and Animals in Research
     
Journal of Addiction Medicine consent policy for case reports
ORIGINALITY AND VALIDITY
     
Conflicts of Interest
     
Copyright
     
Authorship
PEER REVIEW
OPEN ACCESS
     
FAQ for open access
PERMISSIONS
MANUSCRIPT SUBMISSION
COVER LETTER
ARTICLE TYPES
     
Reporting guidelines
     
Original Research
     
Brief reports
     
Reviews
     
Clinical Practice Guidelines
     
Commentary and Debate
     
Letters to the Editor
     
Case Reports and Case Series
PREPARATION OF MANUSCRIPT
     
Title page
     
Keywords
     
Abstract
     
Text
     
Abbreviations
     
References
FIGURES AND ARTWORK
SUPPLEMENTAL DIGITAL CONTENT
TABLES
STYLE
AFTER ACCEPTANCE
     
Page proofs and corrections
     
Reprints
LANGUAGE AND TERMINOLOGY GUIDANCE FOR JOURNAL OF ADDICTION MEDICINE (JAM) MANUSCRIPTS

 

JOURNAL SCOPE

Journal of Addiction Medicine is a peer-reviewed journal designed to address the needs of the ­professional practicing in the ever-changing and challenging field of addiction medicine. Under the guidance of an esteemed Editorial Board, the Journal covers a wide range of topics relevant to clinical care and public health, including:

  • addiction and substance use in pregnancy
  • adolescent addiction and at-risk use
  • the drug-exposed neonate
  • pharmacology
  • all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances
  • diagnosis
  • neuroimaging techniques
  • treatment of special populations
  • treatment, early intervention and prevention of alcohol and drug use disorders
  • methodological issues in addiction research
  • pain and addiction, prescription drug use disorder
  • co-occurring addiction, medical and psychiatric disorders
  • pathological gambling disorder, sexual and other behavioral addictions
  • pathophysiology of addiction
  • behavioral and pharmacological treatments
  • issues in graduate medical education
  • recovery
  • health services delivery
  • ethical, legal and liability issues in addiction medicine practice
  • drug testing
  • self- and mutual-help
Back to top of page

ETHICAL/LEGAL CONSIDERATIONS

Patient anonymity and informed consent

It is the author's responsibility to ensure that a patient's anonymity be carefully protected. Authors must verify that any investigation with human subjects reported in the manuscript was performed with informed consent or with a waiver approved by the appropriate ethics board, and following all the guidelines for experimental investigation with human subjects required by the institution(s) and localities with which all the authors are affiliated. If consent was not obtained, explain why. Authors must obtain written consent from people shown in figures and submit written consent with the manuscript.  To further protect anonymity, consider masking eyes.  Names should be removed from any figures or photographs.  See also policy on case report consent.

Back to top of page

Protection of Human Subjects and Animals in Research

For any manuscripts involving human subjects’ research, always include a statement in the methods section describing ethics (institutional review) board review and approval and consent. When reporting experiments on human subjects, author must confirm that the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration, as revised in 2004:

http://www.wma.net/en/30publications/10policies/b3/  If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors must confirm that institutional and national guides for the care and use of laboratory animals were followed.

Back to top of page

Journal of Addiction Medicine consent policy for case reports

There is no universal consensus regarding consent for publication of case reports, except cases that are identifiable can only be published when consent has been obtained.  Note that such consent is different from research participant consent, which applies to systematic investigation of a subject or subjects with intent to generalize the findings.  Consent to publish the details of an individual’s case is obtained to respect the person’s right to privacy. 

Institutional review and ethics boards make determinations about consent for research.  However, even if consent is waived for research and even if a case report is deemed to not constitute research, consent is often required for other reasons (privacy). If a case report or case series is deemed to be research (systematic collection of data with an intent to generalize the findings) then report of approval and relevant consent should be stated as with all other research. When two cases are reported, institutional review or ethics board review is recommended; in general, such review is required when 3 or more cases are reported.

Consent from the subject (or parent/guardian) should be obtained for all case reports.  Consent can be on an institutional document or one similar to the examples below (modified as appropriate), and should be stored for seven years and made available to the editors and publisher on request.  State in the cover letter that written consent to publish a report of the case has been obtained by the subject and that it is available for review by the editors and publisher of the journal.

If the subject is deceased, consent should be provided by family or significant others (next-of-kin).  If consent has not been obtained, the authors must describe the circumstances of how they attempted to obtain consent or why it was not possible.

If consent is not obtained, the editors, alone or in consultation with the publisher and/or peer reviewers, will consider the extent to which the case appears to be anonymous and the exhaustive and reasonable nature of attempts to obtain consent, and whether there is any reason to suspect that a patient might have objected to publication.  The authors should carefully attempt to protect the patient’s identity.  Then the journal will attempt to balance the risk of deductive disclosure with the benefit to public health and science.  Authors should keep in mind however, that even without the inclusion of identifiers, real cases can often be identified by people in the community since cases worthy of reporting are often recognizable.

During the COVID-19 pandemic, physical written consent will be waived if the local practice during the pandemic is to not obtain written consent for clinical care. A digital signature or an audio recording of consent is acceptable in this case. If these are also infeasible (state so and why), then a detailed description of the consent process and what exactly the patient agreed to should be provided. Note that the consent process and elements to which patients are consenting as outlined on the sample documents below should be the same when consent is digital, audio recorded or oral, as when written consent is provided.

Case report manuscripts must state whether consent was obtained, along with any relevant circumstances as described above.

For more guidance in writing case reports, click here to read an editorial on the subject. 

Sample consent forms:
https://resource-cms.springernature.com/springer-cms/rest/v1/content/6633976/data/v2
https://authors.bmj.com/policies/patient-consent-and-confidentiality/  ​
http://journals.bmj.com/site/authors/editorial-policies.xhtml#patientconsent

Back to top of page

ORIGINALITY AND VALIDITY

A submitted manuscript must be an original contribution not previously published (except as an abstract, preprint as defined in the preprint policy, or a preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each person listed as an author is expected to have participated in the study to a significant extent.  Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher. Regarding attempted or actual instances of duplicate publication, plagiarism, or scientific fraud, the Journal adheres to and follows guidance from the Committee on Publication Ethics (COPE) http://publicationethics.org/resources/guidelines

Preprint policy: Preprint servers are online archives of manuscripts as drafted by the authors; these manuscripts have not been peer reviewed and have not been published by journals. Journal of Addiction Medicine will consider article submissions that have been previously posted as preprints on established noncommercial servers (such as bioRxiv and medRxiv) that adhere to industry standards. Such standards include clearly indicating that preprint manuscripts have not undergone peer review. Authors may not initiate a preprint posting or update an existing preprint while the peer-review process is underway at JAM. 

At the time of submission to JAM, authors must indicate in their cover letter that they have posted their articles on a preprint server and provide the digital object identifier (DOI) and URL for the preprint. If JAM decides to accept the submission for publication, then authors must ensure that their article in JAM includes the DOI and link to the preprint and that the preprint is updated with a link to the published version of record in JAM. 

AI Authorship Policy: Authors who use AI tools in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent in disclosing in the Materials and Methods (or similar section) of the paper how the AI tool was used, and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics.​ 

Back to top of page

Conflicts of Interest

Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared.  All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading “Conflicts of Interest and Source of Funding:” For example: Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for Organization X – the CME organizers for Company A. For the remaining authors none were declared.

Sources of support including those from the alcohol, tobacco, pharmaceutical or other relevant interests are to be published included in the published manuscript.

Authors of review articles and commentary/debate articles should not have any relevant financial ties to industry that produces drugs, devices, or tests or other commercial companies with an interest in the topic of the article.

Back to top of page

Copyright

In addition, each author must complete and submit the journal’s copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (www.icmje.org/update.html).

A copy of the form is made available to the submitting author within the Editorial Manager submission process.  Co-authors will automatically receive an Email with instructions on completing the form upon submission.Use the 'Contact Us' link above to contact the Editorial Office with any questions.

Back to top of page

Authorship

Consistent with International Committee of Medical Journal Editors (ICMJE) guidelines (http://www.icmje.org/), all listed authors must meet the following criteria:

  1. substantial contributions to conception or design of the work, or the acquisition, analysis, or interpretation of data for the work
  2. drafting of the work or revising it critically for important intellectual content
  3. final approval of the version to be published
  4. agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Anyone who meets all for criteria should be named as an author, and all authors must meet these criteria. Those who do not meet authorship criteria but who contributed to the work may be named in an acknowledgement section with their permission.

Back to top of page

PEER REVIEW

All papers undergo peer review, except for some commentaries and letters and editorials that may be peer reviewed or reviewed only by the Editors. Manuscripts will be sent to peer reviewers with expertise in the topics of relevance who will be asked to keep the existence of the paper and its contents confidential.  Identity of the peer reviewer is not made known to the author.  Identity of the authors is not masked.  Peer review comments are considered by the editors in the manuscript revision process.

The journal follows guidance as described by the COPE Ethical Guidelines for Peer Reviewers.

Back to top of page

OPEN ACCESS​

Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of submission. Please note that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.

The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published open access. For a list of journals and pricing please visit our Wolters Kluwer Hybrid Open Access Journals page.

Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant Wolters Kluwer an exclusive license to publish the article and the article is made available under the terms of a Creative Commons user license. Please visit our Open Access Publication Process page for more information.

Creative Commons license
Open access articles are freely available to read, download and share from the time of publication under the terms of the Creative Commons License Attribution-Non Commercial No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any commercial purposes, nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission.

Compliance with funder mandated open access policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution (CC BY) license is able to meet that requirement through the available open access license for approved funders. Information about the approved funders can be found here.

Read and Publish Agreements

Wolters Kluwer currently has read-and-publish agreements with institutional consortia listed here.

Corresponding authors who are affiliated with the participating institution and who qualify as eligible authors* can publish their eligible articles open access in the eligible LWW journals at no direct cost to them. Please see your institution's individual policy for guidance on eligible article types and license choice. To qualify for the APC waiver, the corresponding author must provide their participating institution's name and institutional email address in the journal's submission system. On acceptance, the corresponding author will be asked to place an open access order in the publisher's payment portal where they will be able to request the APC be funded in accordance with this agreement. A $0.00 APC will then be applied.

*Eligible authors: Corresponding authors who are teaching and research staff employed by or otherwise accredited to one of the participating institutions as well as students enrolled or accredited to one of the institutions and who want to publish open access articles.

Compliance with National Institutes of Health Accessibility Requirements  
The National Institutes of Health (NIH) requires authors to submit the “post-print" (the final manuscript, in Word format, after peer-review and acceptance for publication but prior to the publisher's copyediting, design, formatting, and other services) of research the NIH funds to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the NIH to PubMed Central.

FAQ for open access
https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access/faq

Back to top of page

PERMISSIONS

Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Wolters Kluwer, Lippincott Williams & Wilkins.

Back to top of page

MANUSCRIPT SUBMISSION

The Journal welcomes pre-submission inquiries regarding suitability if questions remain after authors have reviewed the aims and scope of the Journal and prior papers published. The Journal encourages outlines be submitted for review for Review and Commentary article types; such review allows for editorial feedback but does not guarantee publication of subsequent articles submitted. The Journal does not provide pre-submission review of full articles.

All manuscripts must be submitted online through the new Web site at http://jam.edmgr.com. First-time users: Please click the Register button from the menu above and enter the requested information. On successful registration, you will be sent an e-mail indicating your user name and password. Print a copy of this information for future reference. Note: If you have received an e-mail from us with an assigned user ID and password, or if you are a repeat user, do not register again. Just log in. Once you have an assigned ID and password, you do not have to re-register, even if your status changes (that is, author, reviewer, or editor). Authors: Please click the log-in button from the menu at the top of the page and log in to the system as an Author. Submit your manuscript according to the author instructions. You will be able to track the progress of your manuscript through the system. If you experience any problems, please contact Michael A. Arends, Managing Editor, [email protected]; fax: 858-784-7405.

Back to top of page

COVER LETTER

A cover letter should accompany the submitted manuscript and should attest to the originality of the submission, note any relevant conflicts of interest, and should attest to the authorship criteria above.

Back to top of page

E-Articles

Some articles published in the Journal are published electronically (online) only (e-articles). They are fully formatted, indexed, paginated, and published and appear in the issues' tables of contents both in print and online. Articles will appear online only, at the discretion of the Editors. Publication online only is not an indicator of quality or preference. This process happens after article acceptance for publication. Authors do not participate in the online-only designation. The Journal's policy for Open Access applies equally to both e-articles and articles that appear both online and in print (see section on Open Access).  

Back to top of page

ARTICLE TYPES

Reporting guidelines

All articles submitted, including but not limited to original research, clinical trials, observational studies, case reports and systematic reviews, should follow internationally recognized reporting standards.  Such standards can be found here http://www.equator-network.org/reporting-guidelines/ and here http://www.consort-statement.org/ and here http://www.care-statement.org/ and here http://www.care-statement.org/care-checklist.html

Journal of Addiction Medicine requires, registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication, consistent with ICMJE guidance.

Back to top of page

Original Research

Scientifically rigorous reports of original work that advance the field of Addiction Medicine. Typically, articles will contain new data derived from a sizable series of patients or subjects. The text cannot exceed 3,500 words (which does not include an abstract of no more than 250 words), a maximum of 5 tables and figures (total), and up to 40 references. Word count includes only the main body of text (i.e., not tables, figures, abstracts or references). Additional tables can be submitted in a separate file as supplemental data for posting online. As part of the discussion or concluding remarks sections, the editors strongly encourage authors to provide a bench to bedside correlation, a statement of potential or actual clinical relevance of the findings, to assist the clinician in applying new findings to the practice setting. If the original research is a controlled study of a health care intervention, list the name of the trial registry (consistent with ICMJE policy) and the unique identification number and provide a link to it.

Systematic reviews are also considered original research papers. Such reviews should address a clear and specific clinical question and should carefully describe article selection, summarize and synthesize study quality and results, and present conclusions about the answer to the question.  Systematic reviews often have the need to include long reference lists and many tables.  While these may not exceed the above limits, supplemental content can be provided as above to address these needs.

Case series (e.g., the presentation of ≥ 4 cases in a single article) should be submitted as the Original Research article type. Word count limits for Original Research are applicable to the case series papers. For further information about how to present cases, please see the Case Reports article type below for instructions that may be applicable and relevant.

Original research manuscripts should include a statement or paragraph in the Discussion about clinical relevance or implications for practice or policy.

Back to top of page

Brief reports

These submissions should consist of scientifically rigorous research that can be reported in a shorter format because the work is preliminary, or because the findings are focused, with one major conclusion. The text should be limited to no more than 1200 words, figures and tables limited to no more than 2, and references to 15. The submission should include a structured abstract, and the manuscript should mention in the Discussion the clinical relevance or implications for practice or policy.

Back to top of page

Reviews

JAM welcomes both unsolicited and commissioned reviews.  Consensus statements will be considered as review articles. Systematic reviews are considered Original Research (see above; Original Research guidance, word limits, etc. apply).

For narrative (expert-opinion-based, non-systematic) reviews, we recommend that you submit an outline directly to the editorial office for approval before writing the review. Send the outline to[email protected]. The editors will provide feedback on your outline and a recommendation regarding whether or not to write and submit the manuscript.

Narrative reviews are not intended to be a forum for the presentation of new data or meta-analyses; they are particularly well suited to clinical questions that go beyond one question and instead cover a broader topic area, or to questions that cannot be well addressed by the extant literature in a systematic review. Although narrative reviews may cover broader topic areas than systematic reviews, they should still be quite focused, not comprehensive reviews of large topic areas as might appear in a book chapter or textbook. For narrative reviews, the text cannot exceed 3,500 words with an abstract of no more than 250 words, a maximum of 3 tables and/or figures (total), and up to 50 references. The word count includes only the main body of the text (i.e., not including tables, figures, the abstract, or references). Additional tables or figures can be submitted in a separate file as supplemental digital content for posting online only.​

Back to top of page

Clinical Practice Guidelines

Clinical Practice Guidelines (CPGs) are acceptable for review and publication, in summary/abbreviated form if space does not allow full publication, using the same word/table/figure limit guidance as for reviews.  CPGs will be peer-reviewed as with any other manuscripts published in JAM. In accordance with National Academy of Medicine guidance https://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx, guidelines should be based on systematic review, be developed by a knowledgeable multidisciplinary panel of experts and representatives from key affected groups (all of whom should be listed in the document), should minimize conflicts of interest, should provide a clear transparent account of the process, should explicitly address the strength of the evidence and recommendations, be revised as appropriate.  The abstract should include a description of the guideline, the methods and the main recommendations. Headings should include the rationale for the guideline, the focus of the guideline, the target population, the methods/process, solicited comments and changes, recommendations, implications for care, research and implementation, and a summary.

Back to top of page

Commentary, or Commentary and Debate

Topics addressed may include articles included in the current or recent issue (these are generally invited papers), issues currently before the addiction medicine community (often author-initiated), or other topics at the discretion of the Editors. The text cannot exceed 1500 words, with up to 15 references. Please note that a brief abstract is required for commentaries. Figures and tables are not permitted in Commentary and Debate articles. Commentaries may be standalone papers or in a debate format, which consists of two commentaries submitted in a coordinated fashion espousing opposing views on a topic. The editors recommend submission of a brief proposal/brief outline of the commentary, or commentary and debate to the editorial office for review and recommendations prior to writing and submitting the paper.

Back to top of page

Letters to the Editor

Brief pieces, ideally in reference to an article previously published in JAM. The text cannot exceed 500 words, no more than one table or figure, and up to 10 references. Word count includes only the main body of text (i.e., not tables, figures or references).  Brief research letters are also considered for publication. We do not have a specific deadline for letters. We consider impact, relevance, and time since publication of the original article as part of these considerations. 

Back to top of page

Case Reports 

Brief reports of relevance to the field with potential for impact will be considered. In general case reports and series should address unexpected or new findings, such as side effects, medication interactions, disease presentations, and courses, and/or manifestations of illness that suggest a new scientific understanding. They should have value for medical knowledge and raise questions about current diagnosis and treatment, sometimes suggesting change in practice may be necessary. For the Case Report article type, the manuscript should be limited to the presentation of 1-3 cases. If the manuscript presents ≥ 4 cases (e.g., a case series), then please submit the manuscript under the Original Research article type.​The case(s) should include relevant history, physical and laboratory findings. The report should include a review of prior cases and case series. The manuscript should include an abstract, followed by a brief background and context, the case(s), and a discussion, that in addition to reviewing prior cases, should make clear what the new knowledge is and its implications. Importantly, a statement must appear in the manuscript itself (not merely in the cover letter) concerning patient/case consent. If authors assert that no patient/case consent was required, then a statement must be included in the manuscript explaining why no consent was required. The text cannot exceed 1500 words, no more than one table, no more than one figure or image, and up to 20 references. Word count includes only the main body of text (i.e., not tables, figures or references).  Case reports must address the issue of consent in accordance with the Journal policy. For more guidance in writing case reports, click here to read an editorial on the subject. 

Back to top of page

PREPARATION OF MANUSCRIPT

MANUSCRIPTS THAT ARE NOT DOUBLE-SPACED AND DO NOT HAVE BOTH PAGE AND LINE NUMBERS WILL BE RETURNED TO THE AUTHOR 

Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.

• The file format for the Abstract and Manuscript and any other textual material should be in Microsoft Word only; Adobe PDF and other file formats cannot be processed by the editorial office. 

• Double-space the manuscript. 

• Upload tables and figures as separate files, and order the files so that tables and figures appear at the end of the manuscript (i.e., do not embed tables/figures within the body of the manuscript). 

• Use continuous PAGE NUMBERING, beginning with the title page as Page 1.

• Use continuous LINE NUMBERING for the entire manuscript, starting with the title page, to facilitate review (in Word, see “Layout" and “Line numbers"). 


Back to top of page

Title page

MANUSCRIPTS THAT DO NOT ADHERE EXPLICITLY TO TITLE PAGE REQUIREMENTS WILL BE RETURNED TO THE AUTHOR 

The title page should appear as the first page of the Word file of your manuscript. Include the following on the title page:

• Complete manuscript title

• Authors' full names, highest academic degrees, and affiliations

• Name and address of corresponding author, including fax number, telephone number, and e-mail address

• Sources of support/funding for the work (include disclosure of funding received for this work from any of the following organizations: National Institutes of Health, Wellcome Trust, and Howard Hughes Medical Institute)

• Conflicts of interest (if no conflicts exist, then state "none")

• Abstract word count

• Manuscript word count (not including references, tables, or figure legends)

• Number of references

• Statement of adherence to preprint policy (if a manuscript was posted on a preprint server, then state the preprint server used, the DOI, and a URL for the preprint; see Preprint Policy in "Originality and Validity" section above).  

Back to top of page

Keywords

Authors should provide 3–5 keywords for each article.

Abstract

Limit the abstract to 250 words. Do not cite references in the abstract. Limit the use of abbreviations and acronyms. Original articles should have a structured abstract organized under the following subheads: Objectives, Methods, Results, and Conclusions.

Back to top of page

Text

Number the pages of the Word file of the manuscript, with the title page as page 1. Organize the manuscript into six main headings: Introduction, Methods, Results, Discussion, Conclusions, and Acknowledgments. Define abbreviations at first mention in text and in each table and figure. If a brand name is cited, supply the manufacturer’s name and address (city and state/country). Acknowledge all forms of support, including pharmaceutical and industry support, in an Acknowledgment paragraph.

Back to top of page

Abbreviations

For a list of standard abbreviations, consult the Council of Biology Editors Style Guide (available from the Council of Science Editors, Drohan Management Group, 12100 Sunset Hills Road, Suite 130, Reston, VA 20190) or other standard sources. Write out the full term for each abbreviation at its first use unless it is a standard unit of measure.

Back to top of page

References

Pattern reference style after the American Medical Association Manual of Style (most recent edition). This reference style is available in all major reference software programs. The authors are responsible for the accuracy and completeness of the references. Cite references in text in the order of appearance as superscript numerals at the end of a wordor after punctuation.2 (The preceding numerals are examples.) Do not link the references to the text. Cite unpublished data, such as papers submitted but not yet accepted for publication or personal communications, in parentheses in the text. If there are more than six (6) authors and/or editors, name only the first three (3) and then use "et al". Journal references should include the issue number in parentheses after the volume number. Refer to the List of Journals Indexed in Index Medicus for abbreviations of journal names, or access the list at http://www.nlm.nih.gov/tsd/serials/lji.html. Sample references are given below:

1.       Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772-1778.

2.       Murray CJL. Maximizing antiretroviral therapy in developing countries: the dual challenge of efficiency and quality [published online December 1, 2014]. JAMA. doi:10.1001/jama.2014.16376

3.       Centers for Medicare & Medicaid Services. CMS proposals to implement certain disclosure provisions of the Affordable Care Act. http://www.cms.gov/apps/media/press/factsheet.asp?Counter=4221. Accessed January 30, 2012.

4.       McPhee SJ, Winker MA, Rabow MW, Pantilat SZ, Markowitz AJ, eds. Care at the Close of Life: Evidence and Experience. New York, NY: McGraw Hill Medical; 2011.

References any format you like: ON INITIAL SUBMISSION only, references can be in any consistent format. They must all include: author names, article, book or chapter title, publication year, volume and issue or edition, and page numbers (start and end). Prior to acceptance for publication (e.g., when editors request a revision), the author will be required to revise the references in the manuscript such that they are in the correct numerical AMA style (see above). This process allows for ease of submission, with the need for authors to meet journal style requirements only when it becomes more likely that the paper will be published.


Back to top of page

FIGURES AND ARTWORK

A) Creating Digital Artwork

  1. Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
  2. Create, Scan and Save your artwork and compare your final figure to the Digital Artwork Guideline Checklist (below).
  3. Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.

B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork:

  • Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High resolution PDF files are also acceptable.
  • Crop out any white or black space surrounding the image.
  • Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file.
  • Photographs, radiographs and other halftone images must be saved at a resolution of at least 300 dpi.
  • Photographs and radiographs with text must be saved as postscript or at a resolution of at least 600 dpi.
  • Each figure must be saved and submitted as a separate file. Figures should not be embedded in the manuscript text file.

Remember:

  • Cite figures consecutively in your manuscript.
  • Number figures in the figure legend in the order in which they are discussed.
  • Upload figures consecutively to the Editorial Manager web site and enter figure numbers consecutively in the Description field when uploading the files.

Color figures

The journal accepts for publication color figures that will enhance an article. Authors who submit color figures will receive an estimate of the cost for color reproduction. If they decide not to pay for color reproduction, they can request that the figures be converted to black and white at no charge. The authors may also request that their color figures be posted online only. The color processing fee is waived when authors elect to pay for Gold Route or Hybrid open access.

Figure legends

Include legends for all figures. They should be brief and specific, and they should appear on a separate manuscript page after the references. Use scale markers in the image for electron micrographs, and indicate the type of stain used.

Back to top of page

SUPPLEMENTAL DIGITAL CONTENT

Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to LWW journals that enhance their article's text to be considered for online posting. SDC may include standard media such as text documents, graphs, audio, video, etc. On the Attach Files page of the submission process, please select Supplemental Audio, Video, or Data for your uploaded file as the Submission Item. If an article with SDC is accepted, our production staff will create a URL with the SDC file. The URL will be placed in the call-out within the article. SDC files are not copy-edited by LWW staff, they will be presented digitally as submitted. For a list of all available file types and detailed instructions, please visit http://links.lww.com/A142.

SDC Call-outs
Supplemental Digital Content must be cited consecutively in the text of the submitted manuscript. Citations should include the type of material submitted (Audio, Figure, Table, etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list number, and provide a description of the supplemental content. All descriptive text should be included in the call-out as it will not appear elsewhere in the article.
Example:
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive.

List of Supplemental Digital Content
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. Include the SDC number and file type of the Supplemental Digital Content. This text will be removed by our production staff and not be published.
Example:
Supplemental Digital Content 1.wmv

SDC File Requirements
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 MBs, authors should first query theJjournal office for approval. For a list of all available file types and detailed instructions, please visit
http://links.lww.com/A142.

Back to top of page

TABLES

Create tables using the table creating and editing feature of your word processing software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. Group all tables in a separate file. Cite tables consecutively in the text, and number them in that order. Each table should appear on a separate page and should include the table title, appropriate column heads, and explanatory legends (including definitions of any abbreviations used). Do not embed tables within the body of the manuscript. They should be self-explanatory and should supplement, rather than duplicate, the material in the text.

Back to top of page

STYLE

Journal of Addiction Medicine has specific style regarding drug names, drug manufacturers, and units. Refer to drugs and therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. Use code numbers only when a generic name is not yet available. In that case, supply the chemical name and a figure giving the chemical structure of the drug. Capitalize the trade names of drugs and place them in parentheses after the generic names. To comply with trademark law, include the name and (city and state/country) of the manufacturer of any drug, supply, or equipment mentioned in the manuscript. 

Use the metric system to express units of measure and degrees Celsius to express temperatures, and use SI units rather than conventional units. 

In presenting p-values, please display 2 decimal places for 0.99>=p>=0.01; 3 decimal places for .01>p>=0.001; and for smaller values express as "p<.001".​

Back to top of page

AFTER ACCEPTANCE

Page proofs and corrections

Corresponding authors will receive electronic page proofs to check the copyedited and typeset article before publication. Portable document format (PDF) files of the typeset pages will be sent to the corresponding author by Editorial Manager task assignment. Complete instructions will be provided with the task assignment for accessing the article proof. It is the author’s responsibility to ensure that there are no errors in the proofs. Changes that have been made to conform to journal style will stand if they do not alter the authors’ meaning. Only the most critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of previously accepted material will be disallowed. The publisher reserves the right to deny any changes that do not affect the accuracy of the content. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Proofs must be checked carefully and corrections submitted in Editorial Manager within 24 to 48 hours of receipt, as requested in task assignment letter.

Back to top of page

Reprints

Authors will receive an email notification with a link to the order form soon after thier article publishes in the journal - https://shop.lww.com/author-reprint. Reprints are normally shipped 6 to 8 weeks after publication of the issue in which the item appears. Contact the Reprint Department, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201; by fax at 410-528-4434; or by e-mail at: [email protected] with any questions. 

Back to top of page

LANGUAGE AND TERMINOLOGY GUIDANCE FOR JOURNAL OF ADDICTION MEDICINE (JAM) MANUSCRIPTS

The Editors strongly encourage use of precise terminology by authors when submitting manuscripts to Journal of Addiction Medicine.  The following guidelines reflect current diagnostic trends, are precise, and are respectful of persons with the spectrum of substance use disorders.

http://journals.lww.com/journaladdictionmedicine/Citation/publishahead/International_Statement_Recommending_Against_the.99656.aspx
http://journals.lww.com/journaladdictionmedicine/Citation/2015/12000/Things_that_Work,_Things_that_Don_t_Work,_and.1.aspx
http://www.parint.org/isajewebsite/terminology.htm 

https://journals.lww.com/journaladdictionmedicine/Fulltext/2021/02000/Recommended_Use_of_Terminology_in_Addiction.2.aspx​


  1. Please use “person first” language (e.g. “person/patient/participant with alcohol use disorder”, rather than “alcoholic”).  “Addict” and “alcoholic,” while popular among some patients and the lay public, can be stigmatizing, dehumanizing, and they do not reflect the very human condition of addiction.  Patients are not “addicts” or “alcoholics” but instead are people or persons with medical illnesses defined by consensus-driven medical terms such as “alcohol use disorder,” “opioid use disorder,” “gambling disorder.” 
  2. Do not use the word “abuse” in reference to substance use unless referring to a diagnosis in pre-DSM 5 versions of the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM).  Similarly do not use the word “abuser.”  “Use” is often the appropriate replacement for “abuse.” Instead of “drug of abuse” use “addictive drug” or “psychoactive drug” or “potentially addictive drug.” We are aware of literature that studies “abuse potential” and recognize there may not be a suitable replacement for that term.
  3. Preferred terms for the disease include substance use disorder, alcohol use disorder, drug use disorder, gambling disorder (DSM-defined terms), and addiction (when used as defined by American Society of Addiction Medicine).  Use of terms in other diagnostic systems is acceptable provided the terms are used as defined. Examples might include “dependence” when referring to pre-DSM 5 or International Classification of Diseases (ICD) diagnoses, or the ICD diagnosis harmful use.  Note that drug should generally not be used when the more appropriate term is medication.
  4. Terminology that attempts to quantify or risk stratify substance use or gambling should be defined within the manuscript.  However, we recommend to the author to:
    • Avoid using the imprecise terms “misuse,” “problem use,” “inappropriate use,” or “binge or binge drinking.”  For example “binge” has been used to a mean heavy drinking episode as defined by number of drinks per unit time, but also as several days of continuous heavy use. “Misuse” can be used to describe use of a prescription medication beyond that prescribed though use without a prescription may be better described as “non-medical.”
    • “Moderate” drinking is non-specific and implies associations with values or outcomes.  “Low” risk or “lower” risk is preferred, or simply specify the amount (e.g. fewer than 2 drinks per day).
    • Preferred terms for use that risks health consequences include “at-risk” or “risky” or “hazardous use.”  “Harmful use” is an ICD diagnosis and its use should be restricted to that diagnosis.  “Problem use” can refer to use associated with consequences that do not meet criteria for a substance use disorder/addiction.  “Unhealthy use” refers to the full spectrum from risky use to a disorder.  http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2014/08/01/terminology-related-to-the-spectrum-of-unhealthy-substance-use
  5. Use medical, not non-medical language:

  1. Avoid inaccurate or imprecise terms:
    • “Opiates” refer to naturally occurring or derived substances (e.g. morphine, heroin).  “Opioids” is a broader term that includes synthetics and semi-synthetics.
    • “Adherence” is preferred over “compliance” when referring to use of health services or medications. 
    • For specificity, “history of” and “active” should be avoided in favor of more specific descriptions (e.g. “past 30-day use,” “current [past year] diagnosis”).
    • Avoid “substitution” therapy”.  “Substitution” is not a correct characterization of medication treatment (for example, opioid agonist treatment does not generally produce euphoria or short-lived increases in blood opioid levels).  Thus, for opioids, “agonist treatment” or “opioid agonist treatment” are preferred.
    • The Journal recommends against using the term “microdosing” to describe low dose buprenorphine. “Microdosing” has a range of meanings in the literature but was originally used to mean a sub-therapeutic dose used to determine pharmacokinetics by the Food and Drug Administration in the US, which is not consistent with the meaning when used to refer to low buprenorphine doses given to start the medication in those with physical dependence to high dose opioid agonists. Authors may use the term once, in quotes, when defining low-dose buprenorphine, and not in the title of the paper (e.g. low-dose buprenorphine (sometimes referred to inaccurately as “microdosing”)).    ​
  2. Avoid stigmatizing language:
    • Do not use “dirty” or “clean” urine or test results, use instead “positive” or “negative” urine or “urine positive for cocaine”, or “cocaine detected,” etc.
    • Do not use “drunk, pothead, crackhead, meth addict, etc.”  Instead use “patient with [insert substance] use disorder.”
    • Do not use “frequent flyer” or “recidivist”.  Instead use “patient with multiple relapses.”
    • Avoid stating that the patient failed treatment.  Instead note that the treatment failed or was not efficacious or effective.

Physicians generally encourage patients and research participants to use commonly accepted medical terminology. For example, patients are taught about “diabetes” instead of “sugar” by health care workers. It has been acceptable for patients or research participants to use “vernacular/slang” language when discussing substance use with clinicians.  This may result in confusion or even suboptimal care since healthcare workers may be unfamiliar with common use of lay terms.  In the practice of Addiction Medicine, or in the reporting of peer-reviewed papers in JAM, the use of humanizing, non-stigmatizing, medically-defined, precise, and professional consensus-driven terminology is important. This will help assure that patients receive respectful high quality treatment and that communication is as clear as possible.

References:

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013

Broyles LM, Binswanger IA, Jenkins JA, Finnell DS, Faseru B, Cavaiola A, Pugatch M, Gordon AJ.  Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response.  Subst Abus. 2014;35(3):217-21. doi: 10.1080/08897077.2014.930372.

Friedmann PD, Schwartz RP. Just call it “treatment.” Addiction Science & Clinical Practice 2012, 7:10

Samet JH, Fiellin DA.  Opioid substitution therapy—time to replace the term

The Lancet , Volume 385 , Issue 9977 , 1508 - 1509

Kelly JF, Wakeman SE, Saitz R.  Stop talking 'dirty': clinicians, language, and quality of care for the leading cause of preventable death in the United States.  Am J Med. 2015 Jan;128(1):8-9. doi: 10.1016/j.amjmed.2014.07.043. Epub 2014 Sep 3.

Kelly JF, Westerhoff C. Does it matter how we refer to individuals with substance-related problems? A randomized study with two commonly used terms

Int J Drug Policy, 21 (2010), pp. 202–207

Kelly JF, Dow SJ, Westerhoff C. Does our choice of substance-related terms influence perceptions of treatment need? An empirical investigation with two commonly used terms J Drug Issues, 40 (2010), pp. 805–818

Salsitz EA, Miller SC. Perspectives: the language of addiction. American Society of Addiction Medicine News 2002 November/December;17(6):13.

Terminology Related to Addiction, Treatment and Recovery.  http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2014/08/01/terminology-related-to-addiction-treatment-and-recovery

Terminology Related to the Spectrum of Unhealthy Substance Use.  http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2014/08/01/terminology-related-to-the-spectrum-of-unhealthy-substance-use

The Definition of Addiction. http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/12/15/the-definition-of-addiction

Van Boekel LC, Brouwers EP, van Weeghal J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: a systematic review Drug Alcohol Depend, 131 (2013), pp. 23–35

Wakeman SE.  Language and Addiction: Choosing Words Wisely. American Journal of Public Health: April 2013, Vol. 103, No. 4, pp. e1-e2.

doi: 10.2105/AJPH.2012.301191

Back to top of page